neoantigen dna vaccine
Vaccineexperimental
Clinical trial activity
14 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03122106)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Renal Cell · Phase 2
- Central Nervous System Neoplasms · Phase 1
- Glioblastoma · Phase 1
- Lung Neoplasms · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Rhabdomyosarcoma · Early Phase 1
- Small Cell Lung Carcinoma · Phase 2
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- neoantigen dna vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06932861 | Early Phase 1 (Phase 1) | May 1, 2025 | People's Liberation Army of China |
| NCT06314087 | Phase 2 | Mar 31, 2024 | The University of Hong Kong |
| NCT06175221 | Phase 2 | Nov 29, 2023 | Elios Therapeutics, LLC, LumaBridge |
| NCT05743595 | Phase 1 | Oct 27, 2023 | Incyte, Washington University in St. Louis |
| NCT05202561 | Phase 1 | Mar 10, 2022 | Bengbu Medical College |
| NCT04397003 | Phase 2 | Jul 31, 2020 | AstraZeneca, Washington University in St. Louis |
| NCT04015700 | Phase 1 | Oct 31, 2019 | Washington University in St. Louis |
| NCT03988283 | Phase 1 | Sep 30, 2019 | Washington University in St. Louis |
| NCT03807102 | Phase 1/Phase 2 (Phase 2) | Jan 16, 2019 | Central South University, Hunan Provincal Tumor Hospital, Shanghai Houchao Biotechnology Co., Ltd |
| NCT03598816 | Phase 2 | Oct 31, 2018 | MedImmune, Washington University in St. Louis |
| NCT03532217 | Phase 1 | Sep 14, 2018 | Bavarian Nordic, Bristol-Myers Squibb, Prostate Cancer Foundation, Washington University in St. Louis |
| NCT03199040 | Phase 1 | Apr 20, 2018 | MedImmune, National Cancer Institute (NCI), National Institutes of Health (NIH), Washington University in St. Louis |
| NCT03122106 | Phase 1 | Jul 1, 2017 | Johns Hopkins University, Washington University in St. Louis |
| NCT03914872 | N/A | — | Washington University in St. Louis |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Washington University in St. Louis | Academic/Hospital | 9 | 9 | 3 | 2017 |
| MedImmune | For profit | 2 | 0 | 2 | 2018 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2020 |
| Bavarian Nordic | For profit | 1 | 0 | 1 | 2018 |
| Bengbu Medical College | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Elios Therapeutics, LLC | For profit | 1 | 1 | 1 | 2023 |
| Hunan Provincal Tumor Hospital | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Incyte | For profit | 1 | 0 | 1 | 2023 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| LumaBridge | For profit | 1 | 0 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2018 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2025 |
| Prostate Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Shanghai Houchao Biotechnology Co., Ltd | Government | 1 | 0 | 1 | 2019 |
| The University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2024 |
18 organizations
Page 1 / 1